Clinical Programs Euroscreen’s lead program ESN364 is advancing into clinical development for women’s health disorders, signaling a strong need for external CRO/clinical operations, regulatory support, biomarker development, and potential licensing or co-development partnerships to accelerate trials and scale supply.

GPCR Partnerships A portfolio of preclinical GPCR targets in neurodegenerative diseases and inflammation creates opportunities for discovery services, medicinal chemistry, ADME/Tox, and in vivo pharmacology collaborations to push assets toward the clinic.

Outsourcing Fit With a small team and private ownership, Euroscreen is likely receptive to outsourced discovery, formulation, analytical development, and early-phase manufacturing partnerships to de-risk development and scale outputs efficiently.

Investor-Supported Backed by Vesalius Biocapital, SRIW and BNP Paribas Fortis Private Equity, Euroscreen may be open to licensing, co-development, or strategic alliances that align with investor interests and help accelerate value milestones.

EU & Sustainability Located in Belgium with a demonstrated emphasis on sustainability such as PVC-free Xpert screen material, Euroscreen could be a fit for green supply chain partnerships, EU grant collaborations, or regulatory-friendly alliances that emphasize environmental responsibility.